ENDRA Life Sciences Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.299 USD | -1.22% | -8.48% | -85.90% |
Mar. 28 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.90% | 3.3M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Auditor Raises 'Going Concern' Doubt